RheaVita provides continuous freeze-drying technology for (bio)pharmaceutical products. Their patented technology integrates all freeze-drying process steps into one continuous production line, resolving the shortcomings of traditional batch freeze-drying and providing new formulation opportunities. In the BAXERNA project, RheaVita will optimize its lyophilization process protocols to freeze-dry candidate vaccine formulations and test their stability.